Skip to content
DataLookout
Menu

KEEPsAKE2NCT03671148

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

StatusActive, Not Recruiting
PhasePhase 3
SponsorAbbVie
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 28 versions: 25 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 6 words Show 5 more changesShow less
    • Sponsor refiled this as active, not recruiting (was completed)
    • Study completion date: Jun 4, 2026 to Jan 2029
    • Secondary endpoints: details revised at 10 of 10 entries
    • Site details revised at 138 of 138 sites
    • Publications: details revised at 9 of 9 entries
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Jun 2026 to Jun 4, 2026
    v27
  3. Minor Study completion date: Jun 12, 2026 to Jun 2026v26
  4. Minor Study completion date: May 18, 2024 to Jun 12, 2026
    • Study description revised
    v23
  5. Minor Study completion date: Mar 22, 2024 to May 18, 2024v22
Show 19 earlier versionsHide 19 earlier versions
  1. Notable Results first posted: Mar 2, 2022v21
  2. Notable Eligibility criteria expanded, about 44 wordsv20 Show 8 more changesShow less
    • Primary endpoint revised
    • Enrollment target: estimated 420 to confirmed 444
    • Study completion date: May 17, 2024 to Mar 22, 2024
    • Interventions: placebo for rizankizumab (Biological), risankizumab (Biological) to Placebo (Biological), Risankizumab (Biological)
    • Secondary endpoints revised (10)
    • Study description expanded, about 131 words
    • Study sites revised (138)
    • Publications: details revised at 1 of 9 entries
  3. Minor Enrollment target: 444 to 420
    • Study sites revised (138)
    v18
  4. Notable Eligibility criteria revisedv17 Show 5 more changesShow less
    • Enrollment target: 429 to 444
    • Study sites: 139 to 138
    • Primary completion date changed from estimate of Jun 19, 2020 to Jun 22, 2020
    • Secondary endpoints: 9 to 10
    • Study title revised
  5. Minor Enrollment target: 444 to 429
    • Study sites: 143 to 139
    • Primary completion date: Jan 29, 2021 to Jun 19, 2020
    v16
  6. Notable Primary completion date: Jun 19, 2020 to Jan 29, 2021
    • Primary endpoint revised
    • Study sites: 147 to 143
    • Secondary endpoints: 7 to 9
    v15
  7. Minor Study sites: 152 to 147v14
  8. Notable Eligibility criteria expanded, about 4 wordsv13 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 420 to confirmed 444
    • Study sites: 154 to 152
    • Primary completion date: Jan 29, 2021 to Jun 19, 2020
    • Study completion date: May 16, 2024 to May 17, 2024
  9. Minor Study sites: 172 to 154
    • Study completion date: Dec 27, 2024 to May 16, 2024
    v12
  10. Minor Site details revised at 22 of 172 sitesv11
  11. Minor Study sites revised (172)v10
  12. Minor Study sites: 173 to 172v9
  13. Minor Study sites: 172 to 173v8
  14. Minor Study sites: 169 to 172v7
  15. Minor Study sites: 165 to 169v6
  16. Minor Study sites: 169 to 165v5
  17. Minor Study sites: 168 to 169
    • Start date: Mar 8, 2019 to Mar 7, 2019
    v4
  18. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 113 to 168
    • Study completion date: Nov 1, 2024 to Dec 27, 2024
    • Start date changed from estimate of Feb 22, 2019 to Mar 8, 2019
    v3
  19. Minor Study sites: 0 to 113
    • Study completion date: Dec 27, 2024 to Nov 1, 2024
    • Start date: Feb 26, 2019 to Feb 22, 2019
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24
Timeframe: Baseline and Week 24

Secondary (10)

Change From Baseline In Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24
Percentage Of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24
Percentage of Participants With an ACR20 Response at Week 16
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
Show 5 moreShow less
Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24
Percentage of Participants With Resolution of Enthesitis at Week 24
Percentage of Participants With Resolution of Dactylitis at Week 24

Arms and interventions

RisankizumabExperimental

Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

PlaceboPlacebo comparator

Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

Biologicals: Placebo, Risankizumab

Sites

138 sites in 25 countries

United States 55, Argentina 7, Australia 5, Canada 5, Israel 5, Poland 5, Spain 5, Belgium 4, Germany 4, Hungary 4, Sweden 4, United Kingdom 4, Estonia 3, Greece 3, Italy 3, Netherlands 3, New Zealand 3, Portugal 3, South Africa 3, Brazil 2, Denmark 2, Finland 2, France 2, Puerto Rico 1, Singapore 1